Vusolimogene Oderparepvec not checked
Replimune, Inc. · RP1
FollowEvery change as it happens, and a Monday email
Trials
5 active
6 in total · 5 in the EU
Targets
—
None known yet
What this is
- How it works
- A gene therapy: delivers a gene into the patient's cells so they make a protein they lack.-gene: gene therapy substances WHO name stem
- Tested for
- Advanced Melanoma, Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma and 4 more
- Main trialPhase 3
- “This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.”In the company’s words, NCT06264180 on ClinicalTrials.gov
- Other names
- RP1 · VO
Other drugs for Advanced Melanoma
- PembrolizumabMerck & Co. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
- BCD-217Biocad · Phase 3
- ISCIB1+Scancell Ltd · Phase 3
Coming up3
- Jun 2028Phase 2 trial completes · ClinicalTrials.gov
- Jul 2029Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Sep 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Sep 2030 | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | |
| Phase 2Active, not recruiting | Sep 2025 | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer | |
| Phase 2Active, not recruiting | Jun 2028 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) | |
| Phase 1/2Active, not recruiting | Jul 2029 | Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies | |
| Phase 2Ended | not given | "neoBREASTIM": A Phase 2 Study of Atezolizumab plus RP1 oncolytic immunotherapy in the NeoAdjuvant setting of Triple-Negative Breast Cancer (TNBC) | |
| Phase 4Authorised | not given | Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026